treatment
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF receives $2.8 million grant to study rare disorder
The grant will provide Bob Axtell with $2.8 million to study NMO and investigate its similarities to other autoimmune diseases, particularly MS.
Joint interest: Understanding different types of arthritis
Arthritis is the leading cause of disability in the U.S., but it isn’t just one disease.
Discovery could help treat Tylenol overdoses
New research from OMRF has pinpointed the cause of liver bleeding during acetaminophen overdose, as well as a possible treatment.
Experts propose improving clinical trials for lupus
The goal of the new white paper is to create a dramatic shift in how lupus clinical trials are conducted so effective treatments can stand a chance to succeed.
